CYTK
Cytokinetics, Incorporated · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -7.1% ·
share flow -0.7% ·
net new positions -7.7%
· formula
Broad distribution: falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 11.48K | $711,878 | n/a | −1 |
| Q2 2026 | 126 | +7 | 95.69M | $8.15B | +10 | −4 |
| Q1 2026 | 123 | +1 | 87.96M | $5.79B | +8 | −8 |
| Q4 2025 | 121 | -1 | 92.45M | $5.87B | +2 | −2 |
| Q3 2025 | 19 | +2 | 69.14M | $3.80B | +2 | −1 |
| Q2 2025 | 15 | -2 | 62.06M | $2.05B | n/a | −2 |
| Q1 2025 | 14 | +1 | 26.36M | $1.06B | +1 | n/a |
| Q4 2024 | 13 | -1 | 25.19M | $1.18B | n/a | −1 |
| Q3 2024 | 13 | +2 | 19.21M | $1.01B | +2 | n/a |
| Q2 2024 | 11 | n/a | 17.42M | $943.61M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 7.89M | +1.5% | $371.08M | 0.1% | ▲ Add | 3 | SEC ↗ ×8 |
| 2 | State Street Global Advisors ✦ (passive) | 6.17M | n/a | $290.11M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 2.84M | -0.2% | $133.69M | 0.0% | ▼ Trim | 3 | SEC ↗ ×2 |
| 4 | T. Rowe Price ✦ | 2.63M | -17.1% | $123.48M | 0.0% | ▼ Trim | 3 | SEC ↗ ×2 |
| 5 | Marshall Wace ✦ | 2.15M | +14.9% | $101.29M | 0.1% | ▲ Add | 3 | SEC ↗ ×3 |
| 6 | Citadel Advisors ✦ | 1.37M | +46.4% | $64.52M | 0.1% | ▲ Add | 3 | SEC ↗ ×2 |
| 7 | Norges Bank ✦ (passive) | 989.72K | -0.3% | $46.56M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 8 | Fisher Asset Management ✦ | 616.49K | +13.7% | $29.00M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 9 | Renaissance Technologies ✦ | 192.17K | -21.4% | $9.04M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 10 | Point72 Asset Management ✦ | 169.91K | -63.4% | $7.99M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 11 | Two Sigma Investments ✦ | 91.17K | -64.8% | $4.29M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 12 | Millennium Management ✦ | 50.52K | -16.6% | $2.38M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 13 | AQR Capital Management ✦ | 33.25K | -11.0% | $1.56M | 0.0% | ▼ Trim | 3 | SEC ↗ ×3 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| D. E. Shaw & Co. | $622,512 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 437 holders, 145.17M shares, $8.22B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 3.50K sh · $224,035
Officer, Director · 7.50K sh · $471,600
Officer · 3.50K sh · $214,830
Officer, Director · 7.50K sh · $490,950
Officer · 3.50K sh · $239,015
Officer, Director · 97.93K sh · $6.79M
Director · 1.00K sh · $72,130
Officer, Director · 7.50K sh · $550,800
Director · 1.00K sh · $74,660
Officer · 3.50K sh · $264,110
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology